Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Int J Med Sci. 2020 Aug 29;17(15):2362-2372. doi: 10.7150/ijms.47356. eCollection 2020.
Cervical cancer is the most common gynecologic malignant tumor, with a high incidence in 50-55-year-olds. This study aims to investigate the potential molecular mechanism of RRM2 for promoting the development of cervical cancer based on The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). RRM2 was found to be significant upregulated in cervical tissue (<0.05) by extracting the expression of RRM2 from TCGA, GSE63514, GSE7410, GSE7803 and GSE9750. Survival analysis indicated that the overall survival was significantly worse in the patients with high-expression of RRM2 (<0.05). The top 1000 positively/negatively correlated genes with RRM2 by Pearson Correlation test were extracted. The gene co-expression network by Weighted Gene Co-Expression Network Analysis (WGCNA) with these genes and the clinical characteristics (lymphocyte infiltration, monocyte infiltration, necrosis, neutrophil infiltration, the number of normal/stromal/tumor cells and the number of tumor nuclei) was constructed. By screening the hub nodes from the co-expression network, results suggested that RRM2 may co-express with relevant genes to regulate the number of stromal/tumor cells and the process of lymphocyte infiltration to promote the progression of cervical cancer. RRM2 is likely to become a novel potential diagnostic and prognostic biomarker of cervical cancer and provide evidence to support the study of mechanisms for cervical cancer.
宫颈癌是最常见的妇科恶性肿瘤,高发年龄为 50-55 岁。本研究旨在基于癌症基因组图谱(TCGA)和基因表达综合数据库(GEO)探讨 RRM2 促进宫颈癌发展的潜在分子机制。通过从 TCGA、GSE63514、GSE7410、GSE7803 和 GSE9750 中提取 RRM2 的表达,发现 RRM2 在宫颈组织中显著上调(<0.05)。生存分析表明,RRM2 高表达患者的总体生存率显著降低(<0.05)。通过 Pearson 相关检验提取与 RRM2 呈正/负相关的 top1000 个基因。利用加权基因共表达网络分析(WGCNA)对这些基因和临床特征(淋巴细胞浸润、单核细胞浸润、坏死、中性粒细胞浸润、正常/基质/肿瘤细胞数量和肿瘤细胞核数量)进行基因共表达网络构建。通过从共表达网络中筛选枢纽节点,结果表明 RRM2 可能与相关基因共同表达,从而调节基质/肿瘤细胞数量和淋巴细胞浸润过程,促进宫颈癌的进展。RRM2 可能成为宫颈癌新的潜在诊断和预后生物标志物,为宫颈癌机制的研究提供证据支持。